Tag Archives: Global

Hot Investor Mandate 4: Venture Arm of Global Medical Device Company Looking to Invest In or Partner with Early-Stage Companies Developing Platforms for Regenerative Medicine

26 Apr

A venture arm of a global medical device company that has worked with researchers and physicians for more than 50 years to develop more effective therapeutic tools, is focused on developing research and clinical tools to advance regenerative medicine therapies from the lab to the patient. The firm is focused on early-stage technologies and is flexible in terms of deal structures and partnerships with startup companies, including seed stage equity investments, strategic partnerships, and joint ventures/collaborations. The firm looks to be a dedicated partner working closely with startups to advance technologies and build companies. The firm has a global presence and is open to early-stage companies from around the world.

The firm’s core focus is on tools and bioprocessing platforms for regenerative medicine including, but not limited to, cell and gene therapies. Interests also include therapies that rely on immature or insufficient manufacturing tools and processes. Some examples of the firm’s products include a platelet lysate culture media to expand cell lines, automated fill/finish and thawing devices, a cryogenic vial to protect samples throughout lab processes, a blood filtration system for autologous cell therapy preparation and more.

The firm has no strict requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 4: Toronto-Based Global Firm Seeks to Invest Early-Stage Medical Device, Diagnostics, and Digital Health Companies

19 Apr

A firm based in Toronto that has offices worldwide manages a variety of different investment vehicles including private equity and multi-strategy funds. In the life sciences, the firm makes equity investments typically at Series A; initial investments range from $100,000-$1 million with follow on capital available of $1-3 million. The firm focuses on companies based in North America but has the capacity to invest worldwide.

In the life sciences, the firm focuses on medical devices, diagnostics and digital health companies. The firm prefers to invest in companies that are close to commercialization or which are already generating revenue (for example, device companies must ideally be ready to file for a CE Mark, 510k or Health Canada application).

The firm prefers to invest in experienced entrepreneurs who have deep knowledge of their sector. The firm only invests in companies developing products that have a clear path to market, and which serve a clear need; the firm prefers to invest in companies that are no more than a year from obtaining revenues. As the firm has offices globally, the firm is well placed to help portfolio companies make international distribution or license/royalty agreements. The firm invests in both public and privately-held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 4: Global Organization Provides Seed Capital to Early-Stage Healthcare Technologies Applicable to Emerging Markets

29 Mar

A global charity organization with an established footprint in over 100 countries worldwide, dedicated to tackling the problem of poverty and injustice, has launched a new initiative through its Canada operations. In 2016, the organization built an investment team to support entrepreneurs developing innovative technologies for emerging markets. Currently, this is the organization’s only operation with an investment vehicle.
The organization seeks to invest up to $250K in early-stage social innovations. In addition to providing capital, the organization will take an active role in helping entrepreneurs with growing their companies and providing valuable connections through their global reach.

The organization will consider any early-stage technology in the healthcare sectors that can help address and solve problems in emerging countries, with a high potential for social impact.

The organization does not have specific management team requirements, but prior experience in working with or developing technologies for emerging countries is a plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , , ,

Newer Entries →